Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FTC’s Rahul Rao On Why Agency Targeted Drug-Device Orange Book Patents

Nov 13 2023

• By Brenda Sandburg

FTC orange book Rao — • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

Related Content

Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds

Feb 16 2020

Delisting Of Jazz’s Xyrem Patent In Orange Book Could Spur More Infringement Counterclaims

Nov 22 2022

In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap

Nov 08 2023

FTC Set To Take Enforcement Action Against Drugmakers Over Orange Book Patent Listings

Sep 15 2023

Related Companies

Jazz Pharmaceuticals plc

Avadel Pharmaceuticals plc

Biovail Corp.

Sanofi

Additional Topics

United States Enforcement Generic Drugs Pricing Debate Market Access Regulation Interviews Respiratory Ophthalmic BioPharmaceutical Medical Device

More from Interviews

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window